Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Overview
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Biogen Inc
Bioleaders Corp
Chugai Pharmaceutical Co Ltd
PeptiDream Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Scholar Rock Inc
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drug Profiles
ALG-802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apitegromab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSM-22 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
domagrozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
luspatercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-70240 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Myostatin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Dormant Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Discontinued Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development Milestones
Featured News & Press Releases
Apr 03, 2020: U.S. Food and Drug Administration (FDA) approves Reblozyl (luspatercept-aamt), the first and only erythroid maturation agent, to treat anemia in adults with lower-risk myelodysplastic syndromes (MDS)
Mar 26, 2020: New England Jourl of Medicine Publishes results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia
Mar 24, 2020: Scholar Rock presents data for SRK-015 at the Muscular Dystrophy Association Clinical and Scientific Conference
Feb 06, 2020: Scholar Rock presents data for SRK-015 at the SMA Europe 2nd Intertiol Scientific Congress
Jan 09, 2020: New England jourl of medicine publishes results of pivotal phase 3 Reblozyl (luspatercept-aamt) MEDALIST trial
Dec 09, 2019: Reblozyl (luspatercept-aamt) studies evaluating treatment of Anemia in rare blood diseases presented at American Society of Hematology (ASH) annual meeting
Dec 06, 2019: Bristol-Myers Squibb and Acceleron Pharma provide update on FDA Advisory Committee for Reblozyl (luspatercept-aamt)
Dec 03, 2019: Bristol-Myers Squibb and Acceleron Pharma announce FDA Advisory Committee will review Reblozyl (luspatercept-aamt) for Use in patients with myelodysplastic syndromes
Nov 19, 2019: Scholar Rock reports prelimiry pharmacokinetic and pharmacodymic data from TOPAZ phase 2 trial of SRK-015 for the treatment of patients with spil muscular atrophy
Nov 11, 2019: Celgene-Acceleron’s Reblozyl gets US approval to treat aemia
Nov 08, 2019: FDA approves REBLOZYL (luspatercept-aamt) for the treatment of anemia in adults with beta thalassemia who require regular red blood cell transfusions
Nov 06, 2019: Celgene to present abstracts on Luspatercept at American Society of Hematology (ASH) 2019 Annual Meeting
Nov 06, 2019: Acceleron announces Luspatercept presentations at the 61st American Society of Hematology Annual Meeting
Oct 02, 2019: Scholar Rock to Present Preclinical and Phase 1 Clinical Data on SRK-015 at the World Muscle Society Congress
Sep 05, 2019: Scholar Rock announces appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Acceleron Pharma Inc, H1 2020
Pipeline by Biogen Inc, H1 2020
Pipeline by Bioleaders Corp, H1 2020
Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
Pipeline by PeptiDream Inc, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Pipeline by Scholar Rock Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020